Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Executive Summary

Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.

Advertisement

Related Content

Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Merck's Promising Early Alzheimer's Data Can't Quell Efficacy Concerns
Grifols-Backed Biotech Sees Early Promise With Alzheimer's Vaccine
Anavex Stock Price Crash: A Fault By Trial Design?
TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study
Full Monty On Pfizer’s Failed 5-HT6 Alzheimer’s Drug Leaves Hope For Class
AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes
Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs
Investors back Avraham Pharmaceuticals' Alzheimer's disease study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel